Biosimilars in the Era of Artificial Intelligence-International Regulations and the Use in Oncological Treatments.

This research is based on three fundamental aspects of successful biosimilar development in the challenging biopharmaceutical market. First, biosimilar regulations in eight selected countries: Japan, South Korea, the United States, Canada, Brazil, Argentina, Australia, and South Africa, represent the four continents. The regulatory aspects of the countries studied are analyzed, highlighting the challenges facing biosimilars, including their complex approval processes and the need for standardized regulatory guidelines. There is an inconsistency depending on whether the biosimilar is used in a developed or developing country. In the countries observed, biosimilars are considered excellent alternatives to patent-protected biological products for the treatment of chronic diseases. In the second aspect addressed, various analytical AI modeling methods (such as machine learning tools, reinforcement learning, supervised, unsupervised, and deep learning tools) were analyzed to observe patterns that lead to the prevalence of biosimilars used in cancer to model the behaviors of the most prominent active compounds with spectroscopy. Finally, an analysis of the use of active compounds of biosimilars used in cancer and approved by the FDA and EMA was proposed.

Speculative computing for AAFM solutions in large-scale product configurations.

Parallel computing is a current algorithmic approach to looking for efficient solutions; that is, to define a set of processes in charge of performing at the same time the same task. Advances in hardware permit the massification of accessibility to and applications of parallel computing. Nonetheless, some algorithms include steps that require or depend on the results of other steps that cannot be parallelized. Speculative computing allows parallelizing those tasks and reviewing different execution flows, which can involve executing invalid steps. Speculative computing solutions should reduce those invalid flows. Product configuration refers to selecting features from a set of available options respecting some configuration constraints; a not complex task for small configurations and models, but a complex one for large-scale scenarios. This article exemplifies a videogame product line feature model and a few configurations, valid and non-valid, respectively. Configuring products of large-scale feature models is a complex and time-demanding task requiring algorithmic solutions. Hence, parallel solutions are highly desired to assist the feature model product configuration tasks. Existing solutions follow a sequential computing approach and include steps that depend on others that cannot be parallelized at all, where the speculative computing approach is necessary. This article describes traditional sequential solutions for conflict detection and diagnosis, two relevant tasks in the automated analysis of feature models, and how to define their speculative parallel version, highlighting their computing improvements. Given the current parallel computing world, we remark on the advantages and current applicability of speculative computing for producing faster algorithmic solutions.